The AI landscape doesn't move in one direction — it lurches. Some techniques leap from experiment to table stakes in a single quarter; others stall against regulatory walls, technical ceilings, or organisational inertia that no amount of hype can dislodge. Knowing which is which is the hard part. The State of Play cuts through the noise with a rigorously maintained index of AI techniques across every major business domain — classified by maturity, evidenced by real-world adoption, and updated daily so you always know where you stand relative to the field. Stop guessing. Start knowing.
A daily newsletter distilling the past two weeks of movement in a domain or two — delivered to your inbox while the index updates in the background.
Each dot marks the weighted maturity of practices within a domain — hover for a brief summary, click for more detail
AI-enhanced surgical robots that augment surgeon capabilities with precision guidance, tremor compensation, and visualisation. Includes da Vinci-style teleoperated systems with AI overlay; distinct from semi-autonomous surgery which performs procedure steps independently.
Surgeon-assisted surgical robotics is a mature, proven practice whose central question has shifted from clinical validation to economic and geographic accessibility. Teleoperated platforms -- led by Intuitive's da Vinci and now challenged by Medtronic's Hugo RAS and others -- augment surgeon precision through tremor filtration, motion scaling, and 3D visualisation, with over 20 million cumulative patient procedures confirming clinical efficacy across urology, general surgery, gynaecology, and colorectal specialties. The ecosystem has entered genuine multi-vendor competition: peer-reviewed head-to-head studies show clinical parity between Hugo RAS and da Vinci, and the fifth-generation da Vinci 5 introduces force feedback that addresses a longstanding limitation. Q1 2026 adoption data shows 847,000 cumulative da Vinci procedures and 11,395 systems in the installed base, with 16% year-over-year procedure growth and 232 new da Vinci 5 placements (near-doubling of previous-year uptake). Yet adoption remains concentrated. Robotic-assisted surgery accounts for roughly 5% of U.S. procedures and under 1% globally, constrained by capital costs of $1.5--2.5 million per system, inconsistent cost-effectiveness evidence, training standardization gaps, and device reliability issues that continue to trigger regulatory recalls. The practice is well past the question of whether it works; what remains unresolved is how broadly it can scale beyond resource-rich hospital systems, given persistent geographic disparities and barriers to equitable access.
Intuitive Surgical's da Vinci platform maintains 70% installed base dominance with accelerating deployment into Q2 2026. Q1 metrics show 847,000 cumulative procedures, 16% year-over-year growth, and 431 new placements (232 da Vinci 5 units, near-doubling prior year). Fifth-generation adoption is expanding from academic centres into ambulatory surgery centres and regional health systems: Sunshine Coast University Hospital (Australia) documented length-of-stay reductions from 5 to 1 night (urology) and 10 days to 1 night (hysterectomy); Lausanne University deployed da Vinci Single Port for minimally invasive procedures through 2.7cm incisions across 6 surgical specialties; Hospital Clinico Valencia achieved 1,000 procedures milestone within 2.8 years, spanning general surgery, urology, thoracic and gynecology. VA Southern Nevada upgraded to da Vinci 5 with force-feedback capability; St. Mary Medical Center (Pennsylvania) deployed da Vinci 5 with force feedback enabling tissue sensing. Da Vinci 5 received CE Mark regulatory approval (April 2026), unlocking pan-European commercial deployment with 150+ enhancements. Addenbrooke's Hospital completed the first East of England robotic pancreaticoduodenectomy (Whipple procedure) using da Vinci Xi with dual surgeon consoles, expanding technical scope into complex oncologic surgery. Korea University Ansan Hospital deployed da Vinci 5 (March 2026), validating multi-platform fleet expansion at high-volume centres (>4,000 prior procedures). Institutional-scale deployment milestones reached in May 2026: NYC Health + Hospitals (the nation's largest public health system) announced 20,000+ cumulative procedures across 19 robots deployed at 10 hospitals with 100+ trained surgeons and 5,000+ annual procedures; Seoul St. Mary's Hospital (Korea) reached 20,000 procedure milestone, confirming geographic breadth of institutional adoption. Peer-reviewed comparative evidence from May 2026 validates oncologic superiority: robotic total gastrectomy reduces blood loss and complications vs laparoscopic approach (Karolinska), and systematic meta-analysis confirms robotic low anterior resection improves perioperative and oncological outcomes in younger rectal cancer cohorts across 16 studies.
Competitive ecosystem expansion accelerated through Q1-Q2 2026. Medtronic's Hugo RAS platform achieved a critical milestone in February 2026 when Cleveland Clinic performed its first U.S. commercial procedure (prostatectomy with next-day discharge), validating competing-platform adoption at a leading academic center. Johnson & Johnson's OTTAVA soft-tissue robot demonstrated 100% robotic completion across a 6-hospital cohort in gastric bypass (May 2026), validating a third major vendor entry into surgeon-assisted robotics. Medtronic Hugo RAS performed first U.S. commercial cases following December 2025 FDA clearance (April 2026), confirming platform entry into an underpenetrated soft-tissue market. European evidence continues to support Hugo RAS clinical parity with da Vinci: an EAU case series (29 patients across 5 centres) demonstrated capability in complex radical cystectomy with intracorporeal urinary diversion. Evolution Healthcare announced planned Hugo RAS deployment at Royston Hospital (New Zealand), signaling geographic ecosystem expansion. Emerging telesurgical deployments validate remote surgical delivery: a bariatric surgeon performed live robotic gastrojejunostomy across 10,000 km (Perth to Indore, India) using SSI Mantra system with <150ms latency, demonstrating technical feasibility for geographic access expansion.
Despite clinical advancement and multi-vendor competition, structural adoption barriers remain entrenched. Randomized controlled evidence (Lancet RCT, 308 patients) found no differences in urinary/sexual function, postoperative complications, or work absence at 12 weeks comparing robotic vs. open radical prostatectomy, indicating that clinical superiority claims are overstated—a critical negative signal for broader adoption. Real-world economic analysis of 1,722 procedures at a French academic hospital (April 2026) found DRG reimbursement inadequate to cover device costs despite documented efficiency gains. Device reliability concerns persist at scale and continue through May 2026: UK MHRA regulatory field safety notice (May 12, 2026) identified reliability concern in da Vinci 5 Tower requiring corrective action; Health Canada Type II recall (April 2026, published May 13) affected da Vinci X and XI systems for defective screws in arm sub-assemblies susceptible to breaking, with specific serial numbers documented; FDA Class II recall (February 2026) affected 219 da Vinci systems for software errors allowing faulty instrument arms to remain in use; Intuitive Surgical settled ~3,000 product liability claims ($67M) from 2004-2013 surgeries with 93+ active lawsuits ongoing (February 2024), documenting sustained post-market safety concerns. Training standardization gaps remain unresolved: consensus from the Robotic Surgery Education Working Group (8 leading educators) identifies lack of standardized proficiency assessment, limited simulation access, and institutional variability despite 100% of U.S. general surgery residencies providing robotic exposure. Regulatory framework challenges for AI-augmented surgical robots remain unsolved—algorithmic bias risks, post-market learning requirements, and liability structures unsuitable for adaptive systems present barriers to next-generation platform advancement. Geographic access disparities persist despite two decades of maturation: UK FOI analysis documented severe NHS inequity (London 28 systems vs. South West 6); 70,000 procedures in England 2023/24 against government targets of 500,000 by 2035. These structural constraints explain persistent adoption plateau: 5% procedural penetration in the U.S., 2% in Europe, under 1% globally, confining technology to resource-rich healthcare systems.
— Prospective cohort study (27 robotic vs 29 open gastrectomy): robotic arm showed lower blood loss (100 vs 175 mL), fewer operative complications (7.4% vs 31%), shorter LOS (7 vs 9 days), equivalent R0 resection and 5-year survival during first-time program implementation.
— J&J OTTAVA achieved 100% robotic completion in 30-patient Roux-en-Y gastric bypass cohort across six hospitals with space-constrained ORs; novel table-integrated architecture (no separate boom/cart) with primary safety/performance endpoints met at 30 days.
— Hugo RAS post-December 2025 FDA urology clearance expanded to 1.25M U.S. general surgery and 468K gynecologic procedures annually; Embrace Gynecology IDE completed enrollment (70 patients, 5 U.S. hospitals); LigaSure RAS and ProGrip mesh accessories approved—signals ecosystem maturation toward multi-vendor multi-specialty surgeon-assisted market.
— Aizu Medical Center (Fukushima Medical University) deployed da Vinci 5 with first-generation force-feedback technology; capability demonstrates 43% reduction in unnecessary tissue loading and enhanced precision for gastric/colon/lung cancer procedures, signaling fifth-generation technology adoption in regional oncology centers.
— Q1 2026 financial metrics confirm 12% installed base growth (11,395 systems), 17% procedure growth outpacing 12% system sales growth, 86% recurring revenue from services/instruments, raising full-year guidance to 13.5-15.5% procedure growth—evidence of mature, sustained market demand.
— Large propensity-matched comparison (91 RATS vs 119 M-VATS): robotic approach delivered superior clinical outcomes (more lymph nodes, less blood loss, shorter operative time/hospital stay) and lower moderate-severe fatigue/sleep disturbance post-op, though with higher costs and recovery trade-offs.
— Regional health system expansion to 23 systems across 10 hospitals (including three newly equipped rural sites) with 30,000 cumulative cases, SRC Network of Excellence accreditation (3 Centers of Excellence, 23 surgeon-credentialed providers), demonstrating institutional commitment and quality validation in underserved geography.
— Hugo RAS platform demonstrated novel oncologic application (lateral-approach lymphadenectomy) with successful 40-year-old penile cancer patient outcome and zero major post-operative complications; extends competing-platform surgical scope beyond initial indication clearance.